Clinical Utility of Selected Disease Activity Markers in Patients with Systemic Lupus Erythematosus

被引:0
|
作者
P. Horák
V. Ščudla
Z. Heřmanová
Z. Pospíšil
L. Faltýnek
M. Budíková
L. Kusá
机构
[1] Third Department of Internal Medicine,
[2] Department of Clinical Immunology,undefined
[3] Department of Nuclear Medicine,undefined
[4] University Hospital of Olomouc,undefined
[5] Olomouc,undefined
[6] Czech Republic,undefined
来源
Clinical Rheumatology | 2001年 / 20卷
关键词
Key words:Adhesive molecules – Antibodies – Cytokines – Disease activity – Neopterin – Systemic lupus erythematosus – Thrombomodulin;
D O I
暂无
中图分类号
学科分类号
摘要
The objective of this study was to assess the utility of measurement of thrombomodulin, antinucleosome antibodies, sVCAM-1, sICAM-1, neopterin, fas ligand, IL-10 and sIL-2R in patients with systemic lupus erythematosus (SLE) and to compare them with traditional markers of SLE activity (anti-dsDNA antibodies, C3, C4) and the ECLAM index of disease activity. The measurement was performed over a 6-month period at three consecutive time points after 3 months in each of the 52 patients with SLE. Anti-dsDNA antibodies, thrombomodulin, antinucleosome antibodies, sVCAM-1m sICAM-1, neopterin, fas ligand, IL-10 and sIL-2R were tested by ELISA technique, while C3, C4 components of complement were tested by nephelometry. Fas ligand and IL-10 did not correlate with the ECLAM index. The rest of the markers showed significant correlation with the disease activity index. Thrombomodulin and anti-dsDNA antibodies reflect in the best way the changing trend in disease activity. Antinucleosome antibodies seem to be a promising marker useful in early diagnosis. Soluble VCAM-1, sICAM-1, neopterin and sIL-2R are interesting molecules with a role in disease pathogenesis, but their practical utility is limited.
引用
收藏
页码:337 / 344
页数:7
相关论文
共 50 条
  • [1] Clinical utility of selected disease activity markers in patients with systemic lupus erythematosus
    Horák, P
    Scudla, V
    Hermanová, Z
    Pospísil, Z
    Faltynek, L
    Budíkovà, M
    Kusà, L
    CLINICAL RHEUMATOLOGY, 2001, 20 (05) : 337 - 344
  • [2] Clinical significance of selected endothelial activation markers in patients with systemic lupus erythematosus
    Kuryliszyn-Moskal, Anna
    Klimiuk, Piotr Adrian
    Ciolkiewicz, Mariusz
    Sierakowski, Stanislaw
    JOURNAL OF RHEUMATOLOGY, 2008, 35 (07) : 1307 - 1313
  • [3] HEMATOLOGICAL PARAMETERS AS THE MARKERS OF DISEASE ACTIVITY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
    Zivkovic, V.
    Stamenkovic, B.
    Stojanovic, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1522 - 1522
  • [4] Neurotrophic factors in systemic lupus erythematosus: markers of disease activity
    Dias, A. F. M. P.
    Lanna, C. C. D.
    Teixeira, A. L.
    Ferreira, G. A.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2021, 39 (06) : 1451 - 1452
  • [5] Triglycerides are markers of disease activity in systemic lupus erythematosus.
    Svenungsson, EK
    Fei, GZ
    Gunnarsson, I
    Lundberg, IE
    Grondal, G
    Klareskog, L
    Frostegard, J
    ARTHRITIS AND RHEUMATISM, 2002, 46 (09): : S214 - S214
  • [6] Utility of the Korean Version of Systemic Lupus Activity Questionnaire, in Clinical Practice: Its Correlation with Disease Activity Indices of Systemic Lupus Erythematosus
    Ahn, Eun Young
    Lee, Wonho
    Moon, Jin Young
    Park, Jin Kyun
    Lee, Eun Young
    Lee, Eun Bong
    Bae, Sang-Cheol
    Shin, Kichul
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [7] Inflammatory markers in saliva and urine reflect disease activity in patients with systemic lupus erythematosus
    Ruacho, Guillermo
    Lira-Junior, Ronaldo
    Gunnarsson, Iva
    Svenungsson, Elisabet
    Bostrom, Elisabeth A.
    LUPUS SCIENCE & MEDICINE, 2022, 9 (01):
  • [8] Markers of atherosclerosis and cardiovascular disease in patients with systemic lupus erythematosus
    Rednic, S
    Damian, LO
    Minodora, M
    Cristea, A
    Bolosiu, HD
    ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 436 - 436
  • [9] Patients' perception of systemic lupus erythematosus disease activity
    Sushchuk, EA
    Torgashina, AV
    RHEUMATOLOGY, 2005, 44 : I137 - I137
  • [10] Subclinical disease activity in systemic lupus erythematosus: Immunoinflammatory markers do not normalize in clinical remission
    Wais, T
    Fierz, W
    Stoll, T
    Villiger, PM
    JOURNAL OF RHEUMATOLOGY, 2003, 30 (10) : 2133 - 2139